ADVENTRX nabs $20M in Icahn-led placement

ADVENTRX Pharmaceuticals has nabbed $20 million in a private placement of its common stock and warrants. Investment funds controlled by Carl Icahn were the largest investors in the transaction, together with Viking Global Investors. Company executives said the proceeds will feed development of its lead compound CoFactor, among other things.

- read this AP report for more

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.